Search
Nkarta Inc
NKTXAdd to Watchlist
3.220USD
+0.370+12.98%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
228.70MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+12.98%
5 Days
+13.78%
1 Month
+16.25%
6 Months
+72.19%
Year to Date
+74.05%
1 Year
+84.00%
Key Figures
2.870Open
3.275High
1.50MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.11%Turnover Ratio
2.850Prev. Close
2.820Low
3.27MTurnover
LossP/E Static
0.68P/B
0.00%Div Yield TTM
-23.72%ROA
3.65052wk High
2.79Volume Ratio
-108.79MNet Profit
71.02MShares
-1.3488EPS TTM
0.92Beta
-30.07%ROE
1.63052wk Low
15.96%Amplitude
--Gross Margin
228.70MMarket Cap
0.64Reward/Risk
4.49%Risk Rate
TradingKey Stock Score of Nkarta Inc
Currency: USD Updated: 2026-07-02Key Insights
Nkarta Inc's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 89 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.80.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Nkarta Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Nkarta Inc Highlights
StrengthsRisks
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.
Undervalued
The company’s latest PE is -2.39, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 58.52M shares, decreasing 30.55% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 1.04M shares of this stock.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
11.800
Target Price
+314.04%
Upside Space
Nkarta Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Nkarta Inc Info
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.
Ticker SymbolNKTX
CompanyNkarta Inc
CEOHastings (Paul J)
Websitehttps://www.nkartatx.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Nkarta Inc (NKTX)?
The current price of Nkarta Inc (NKTX) is 3.22.
What is the symbol of Nkarta Inc?
The ticker symbol of Nkarta Inc is NKTX.
What is the 52-week high of Nkarta Inc?
The 52-week high of Nkarta Inc is 3.65.
What is the 52-week low of Nkarta Inc?
The 52-week low of Nkarta Inc is 1.63.
What is the market capitalization of Nkarta Inc?
The market capitalization of Nkarta Inc is 228.70M.
Is Nkarta Inc (NKTX) currently rated as Buy, Hold, or Sell?
According to analysts, Nkarta Inc (NKTX) has an overall rating of Buy, with a price target of 11.80.
What is the Earnings Per Share (EPS TTM) of Nkarta Inc (NKTX)?
The Earnings Per Share (EPS TTM) of Nkarta Inc (NKTX) is -1.41.